GOVX - GeoVax Labs, Inc. Stock Price, Fair Value and News

1.70USD-0.04 (-2.30%)Market Closed

Market Summary

USD1.70-0.04

Market Closed

-2.30%

GOVX Stock Price

View Fullscreen

GOVX RSI Chart

GOVX Valuation

Market Cap

3.9M

Price/Earnings (Trailing)

-0.14

Price/Sales (Trailing)

47.85

Price/Free Cashflow

-0.14

GOVX Price/Sales (Trailing)

GOVX Profitability

Return on Equity

-51.2K%

Return on Assets

-827.2%

Free Cashflow Yield

-691.71%

GOVX Fundamentals

GOVX Revenue

Revenue (TTM)

81.5K

GOVX Earnings

Earnings (TTM)

-27.8M

Earnings Growth (Yr)

-44.88%

Earnings Growth (Qtr)

22.95%

Breaking Down GOVX Revenue

Last 7 days

9.0%

Last 30 days

16.4%

Last 90 days

-27.7%

Trailing 12 Months

-83.1%

How does GOVX drawdown profile look like?

GOVX Financial Health

Current Ratio

0.87

GOVX Investor Care

Shares Dilution (1Y)

30.94%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2022	356.6K	276.9K	246.5K	81.5K
2021	1.2M	857.2K	472.2K	385.5K
2020	1.5M	1.8M	1.8M	1.8M
2019	1.1M	1.2M	1.2M	1.2M
2018	1.0M	742.0K	843.3K	963.2K
2017	1.1M	1.3M	1.1M	1.1M
2016	372.3K	467.1K	814.0K	828.9K
2015	829.0K	720.1K	491.1K	428.1K
2014	1.8M	1.5M	834.6K	883.0K
2013	2.6M	2.3M	2.7M	2.4M
2012	4.9M	3.8M	3.2M	2.7M
2011	4.7M	4.8M	4.9M	4.9M
2010	0	4.2M	4.7M	5.2M
2009	0	0	0	3.7M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of GeoVax Labs, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 22, 2024	dodd david a	bought	18,663	2.2735	8,209	president, ceo
Feb 21, 2024	dodd david a	bought	1,118	2.15	520	president, ceo
Feb 07, 2024	reynolds mark	bought	5,540	2.77	2,000	cfo
Dec 22, 2023	mckee kelly t. jr.	bought	2,499	0.36	6,944	chief medical officer
Sep 25, 2023	mckee kelly t. jr.	bought	5,019	0.52	9,653	chief medical officer
Aug 25, 2023	dodd david a	bought	19,999	0.57	35,087	president, ceo
Aug 18, 2023	reynolds mark	bought	5,179	0.5179	10,000	cfo
Apr 24, 2023	dodd david a	bought	20,444	0.6389	32,000	president, ceo
Apr 20, 2023	reynolds mark	bought	5,040	0.63	8,000	cfo
Sep 21, 2022	chase randal d	bought	11,000	1.1	10,000	-

Which funds bought or sold GOVX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	STATE STREET CORP	sold off	-100	-35,357	-	-%
May 15, 2024	Royal Bank of Canada	new	-	-	-	-%
May 15, 2024	Royal Bank of Canada	sold off	-100	-	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	new	-	8,942	8,942	-%
May 15, 2024	Tower Research Capital LLC (TRC)	sold off	-100	-3,706	-	-%
May 15, 2024	ARMISTICE CAPITAL, LLC	new	-	356,000	356,000	-%
May 15, 2024	ARMISTICE CAPITAL, LLC	sold off	-100	-587,172	-	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-6.00	-	-%
May 15, 2024	MORGAN STANLEY	new	-	240	240	-%
May 15, 2024	MORGAN STANLEY	sold off	-100	-736	-	-%

Are Funds Buying or Selling GOVX?

Are funds buying GOVX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own GOVX

No. of Funds

Unveiling GeoVax Labs, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	9.99%	3,111,069	SC 13G
Feb 14, 2022	l1 capital global opportunities master fund, ltd.	0%	0	SC 13G/A
Jan 05, 2022	sabby management, llc	12.%	0	SC 13G/A
Feb 10, 2021	cavalry fund i management llc	4.99%	219,335	SC 13G/A
Feb 04, 2021	bigger capital fund l p	3.8%	151,118	SC 13G/A
Jan 08, 2021	sabby management, llc	0.82%	31,313	SC 13G/A
Oct 20, 2020	cavalry fund i management llc	6.8%	242,625	SC 13G
Oct 05, 2020	bigger capital fund l p	4.0%	141,200	SC 13G
Oct 05, 2020	armistice capital, llc	4.99%	188,372	SC 13G

Recent SEC filings of GeoVax Labs, Inc.

View All Filings

Date Filed	Form Type	Document
May 15, 2024	8-K	Current Report
May 14, 2024	10-Q	Quarterly Report
May 14, 2024	424B3	Prospectus Filed
May 14, 2024	424B3	Prospectus Filed
May 14, 2024	424B3	Prospectus Filed
May 14, 2024	424B3	Prospectus Filed
Apr 15, 2024	DEF 14A	DEF 14A
Apr 03, 2024	PRE 14A	PRE 14A
Mar 13, 2024	EFFECT	EFFECT
Mar 11, 2024	CORRESP	CORRESP

Peers (Alternatives to GeoVax Labs, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

GeoVax Labs, Inc. News

Latest updates

GeoVax Labs, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4
Revenue	-	-	-	-	82.00	165	30.00	80.00	110	252	415	441	716	269	333	210	364	299	349	93.00	221	179
Operating Expenses	35.7%	5,388	3,971	2,242	2,510	13,909	1,982	1,566	1,674	1,589	852	889	1,311	860	759	864	1,066	934	1,017	731	-	-
S&GA Expenses	29.9%	1,623	1,249	935	1,179	1,015	757	733	1,072	831	435	427	502	423	291	413	510	472	459	359	357	-
R&D Expenses	38.3%	3,765	2,721	1,307	1,331	12,894	1,224	833	603	757	417	461	809	436	468	451	556	462	558	372	-	-
Interest Expenses	-	-	-	-	-	-	-	531*	755*	802*	134	7.00	1.00	1.00	1.00	1.00	1.00	1.00	625*	625*	208*	-
Net Income	-35.7%	-5,383	-3,968	-2,241	-2,427	-13,743	-1,950	-1,314	-1,562	-1,336	-570	-455	-595	-590	-424	-654	-701	-634	-666	-637	-	-
Net Income Margin	-89.4%	-171.98*	-90.80*	-73.54*	-54.50*	-48.17*	-13.05*	-5.58*	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-83.4%	-7,064	-3,851	-3,853	-4,395	-6,683	-1,661	-1,278	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-63.8%	3,358	9,283	16,201	21,249	27,404	31,348	38,570	33,241	16,855	11,797	18,340	19,817	21,115	10,394	11,756	958	831	469	817	343	473
Current Assets	-63.7%	2,862	7,886	14,800	19,827	25,989	28,939	36,137	32,038	16,637	11,629	18,160	19,657	20,961	10,235	11,735	938	810	447	796	320	448
Cash Equivalents	-88.1%	769	6,453	12,687	17,789	23,850	27,613	34,677	30,902	16,258	11,424	18,107	19,539	20,843	9,884	11,581	711	222	283	569	216	176
Net PPE	-9.3%	190	210	213	224	218	235	249	215	207	157	169	150	143	148	10.00	9.00	10.00	11.00	10.00	12.00	14.00
Liabilities	-	-	-	-	-	-	4,748	6,789	5,368	5,501	7,435	336	359	464	825	942	2,808	2,695	2,043	1,837	1,671	1,680
Current Liabilities	-6.1%	3,304	3,520	7,082	4,086	4,539	4,748	4,789	3,368	3,501	5,435	336	359	452	810	924	2,786	2,670	2,016	1,808	1,639	1,644
Shareholder's Equity	-99.1%	54.00	5,763	9,119	17,164	22,865	26,600	31,781	27,873	11,354	4,362	18,004	19,458	20,651	9,569	10,814	-	-	-	-	-	-
Retained Earnings	-5.6%	-110,213	-104,363	-96,771	-88,362	-82,434	-78,397	-73,013	-69,045	-66,803	-64,375	-50,632	-48,682	-47,368	-45,805	-44,469	-43,898	-43,443	-42,847	-42,256	-41,832	-41,178
Additional Paid-In Capital	0.1%	110,266	110,125	105,864	105,500	105,274	104,995	104,768	96,902	78,148	68,731	68,630	68,134	67,937	55,295	55,203	41,659	41,189	39,341	38,819	38,165	37,899
Accumulated Depreciation	2.9%	700	681	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	16.7%	2,308	1,977	1,780	1,763	1,763	1,756	1,564	848	474	425	423	422	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	14,364	-	-	-	13,239	-	-	-	30,365	-	-	-	7,609	-	-	-	416	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	44.7%	-5,683	-10,277	-5,095	-6,037	-3,762	-7,064	-3,799	-3,833	-4,333	-6,683	-1,633	-1,258	-1,621	-1,541	-283	-566	-358	-280	-343	-456	-317
Share Based Compensation	-39.7%	158	261	298	270	246	251	239	207	205	-	-	87.00	77.00	40.00	6.00	12.00	6.00	37.00	32.00	105	153
Cashflow From Investing	100.0%	-	-18.95	-6.19	-23.80	-	-	-51.87	-20.20	-62.19	-	-27.79	-19.93	-	-154	-2.47	-	-	-3.33	-	-	-4.27
Cashflow From Financing	-100.0%	-	4,062	-	-	-	-	7,626	18,499	9,229	-	230	-25.80	12,580	-526*	11,156	1,056	297	-1.92	697	497	238

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

GOVX Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 4,425,728	$ 2,819,189
General and administrative	1,457,353	1,451,425
Total operating expenses	5,883,081	4,270,614
Loss from operations	(5,883,081)	(4,270,614)
Other income:
Interest income	32,949	232,698
Net loss	$ (5,850,132)	$ (4,037,916)
Basic and diluted:
Net loss per common share (in dollars per share)	$ (2.47)	$ (2.3)
Weighted average shares outstanding (in shares)	2,367,050	1,755,905

GOVX Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Assets [Abstract]
Cash and cash equivalents	$ 768,859	$ 6,452,589
Prepaid expenses	2,093,519	1,433,153
Total current assets	2,862,378	7,885,742
Property and equipment, net	190,113	209,689
Other assets	305,691	1,187,788
Total assets	3,358,182	9,283,219
Current liabilities:
Accounts payable	1,883,844	2,802,950
Accrued expenses	1,420,063	716,931
Total current liabilities	3,303,907	3,519,881
Equity [Abstract]
Common stock, $.001 par value: Authorized shares – 150,000,000 and 600,000,000 at March 31, 2024 and December 31, 2023, respectively; Issued and outstanding shares – 2,308,309 and 1,977,152 at March 31, 2024 and December 31, 2023, respectively	2,308	1,977
Additional paid-in capital	110,265,884	110,125,146
Accumulated deficit	(110,213,917)	(104,363,785)
Total stockholders’ equity	54,275	5,763,338
Total liabilities and stockholders’ equity	$ 3,358,182	$ 9,283,219

About GeoVax Labs, Inc.

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is also developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; GEO-EM01 for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. GeoVax Labs, Inc. has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.

CEO	Mr. David Alan Dodd
WEBSITE	geovax.com
INDUSTRY	Biotechnology
EMPLOYEES	14

GeoVax Labs, Inc. Frequently Asked Questions

What is the ticker symbol for GeoVax Labs, Inc.? What does GOVX stand for in stocks?

GOVX is the stock ticker symbol of GeoVax Labs, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of GeoVax Labs, Inc. (GOVX)?

As of Fri May 17 2024, market cap of GeoVax Labs, Inc. is 3.92 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GOVX stock?

You can check GOVX's fair value in chart for subscribers.

What is the fair value of GOVX stock?

You can check GOVX's fair value in chart for subscribers. The fair value of GeoVax Labs, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of GeoVax Labs, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for GOVX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is GeoVax Labs, Inc. a good stock to buy?

The fair value guage provides a quick view whether GOVX is over valued or under valued. Whether GeoVax Labs, Inc. is cheap or expensive depends on the assumptions which impact GeoVax Labs, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GOVX.

What is GeoVax Labs, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, GOVX's PE ratio (Price to Earnings) is -0.14 and Price to Sales (PS) ratio is 47.85. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GOVX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on GeoVax Labs, Inc.'s stock?

In the past 10 years, GeoVax Labs, Inc. has provided 0.243 (multiply by 100 for percentage) rate of return.